<DOC>
	<DOCNO>NCT01582035</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , pharmacokinetics ( drug absorb bloodstream ) antiviral activity repeat dos TMC647055 give combination telaprevir HCV infect patient . TMC647055 investigate treatment hepatitis C infection . Telaprevir recently approve USA Europe treatment chronic hepatitis C infect patient .</brief_summary>
	<brief_title>Study Examine Multiple Doses TMC647055 Combination With Telaprevir</brief_title>
	<detailed_description>This phase I , open label trial genotype 1 hepatitis C virus ( HCV ) infect patient . The study population consist 16 adult patient . TMC647055 give oral solution telaprevir ( TVR ) give oral tablet . Patients find eligible screen visit divide 2 panel perform sequentially . In first panel , 8 patient receive TMC647055 dose 500 mg twice day combination TVR dose 1125 mg twice day 10 consecutive day . In second panel , 8 subject receive TMC647055 combination TVR 14 day . TMC647055 TVR dose decide base result panel 1 . TMC647055 dose high 1000 mg twice day TVR dose 1125 mg twice day 1500 mg twice day . It could also decide change duration panel 2 10 day . In case , time assessment panel 1 follow . For duration dose 2 panel , patient remain site . Immediately last dose panel 1 2 , patient start extension phase . In phase , patient receive TVR dose 750 mg every 8 hour 12 week combination pegylated interferon alfa ( Peg IFN ) ( 180ug subcutaneous weekly ) ribavirin ( RBV ) ( 1000 1200 mg per day orally depend weight 2 divided dos ) . After receive either 12 36 week PegIFN -RBV treatment dose regimen , depend virus level week 4 12 extension phase . In extension phase , patient come site visit week 2 , 4 , 8 , 12 , 16 , 24 , 36 ( applicable ) 48 ( applicable ) . Patients prematurely drop panel 1 2 , follow-up visit 2 4 week last dose . Patients participate extension phase follow-up visit 4 12 week last dose . Safety tolerability evaluate throughout study .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>genotype 1a 1b HCV infection HCV RNA level &gt; 100,000 IU/mL A document prior relapser patient previous treatment regimen treatmentna√Øve Patient must documentation liver biopsy within 3 year screen visit must agree fibroscan/elastography examination within screen period Patient judge medically stable basis physical examination , medical history , vital sign , 12lead electrocardiogram ( ECG ) perform screen Evidence liver cirrhosis Evidence decompensated liver disease Evidence cause significant liver disease addition hepatitis C receive receive treatment HCV 6 month screen History evidence current abuse alcohol , barbiturate , amphetamine , recreational narcotic drug use , investigator 's opinion would compromise subject 's safety and/or compliance study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>TMC647055HPC1005</keyword>
	<keyword>TMC647055</keyword>
	<keyword>telaprevir</keyword>
</DOC>